Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 1/20 | 0.70 |
| ▸ | HK1 | P19367 | 1/20 | 0.70 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.70 |
| ▸ | PIM1 | P11309 | 2/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 4/20 | 0.33 |
| ▸ | STAT3 | P40763 | 2/20 | 0.33 |
| ▸ | P4HB | P07237 | 3/20 | 0.33 |
| ▸ | PDIA4 | P13667 | 3/20 | 0.33 |
| ▸ | PDIA3 | P30101 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7637697 | 0.95 | NSD2 (0.77) | NSD2HK1HKDC1PIM1IDO1 | |
| SCHEMBL11832717 | 0.86 | NSD2 (0.70) | NSD2HK1HKDC1STAT3MEN1 | |
| SCHEMBL7637705 | 0.80 | PIM1 (0.51) | NSD2HK1HKDC1PIM1IDO1 | |
| SCHEMBL7633252 | 0.75 | NSD2 (0.51) | NSD2HK1HKDC1PIM1IDO1 | |
| SCHEMBL11022246 | 0.70 | NSD2 (0.51) | NSD2HK1HKDC1 | |
| SCHEMBL11019899 | 0.70 | NSD2 (0.54) | NSD2HK1HKDC1 | |
| SCHEMBL10633275 | 0.69 | NSD2 (0.49) | NSD2HK1HKDC1 | |
| SCHEMBL10903809 | 0.69 | NSD2 (0.49) | NSD2HK1HKDC1 | |
| SCHEMBL6215321 | 0.68 | NSD2 (0.48) | NSD2HK1HKDC1 | |
| SCHEMBL17195889 | 0.65 | NSD2 (0.46) | NSD2HK1HKDC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0525073-B1 | ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA | DU PONT (US) | 1994-05-25 | — | — | EP | claimed |
| EP-0525073-A1 | ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA. | DU PONT (US) | 1993-02-03 | — | — | EP | claimed |
| WO-1991015954-A1 | ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-10-31 | — | — | WO | claimed |
| US-20250302797-A1 | COMBINATION THERAPIES FOR TREATING INFLAMMATION | FLAGSHIP PIONEERING INNOVATIONS VI LLC (US) | 2025-10-02 | — | — | US | disclosed |
| EP-0801639-B1 | METHOD FOR PREPARING SUBSTITUTED ANTHRAQUINONES AND USE THEREOF FOR PREPARING RHEINS | GIREX (FR) | 2002-01-02 | — | — | EP | disclosed |
| US-5948924-A | Process for the preparation of substituted anthraquinones and application in the preparation of rheins | GIREX (SOCIETE ANONYME) (FR) | 1999-09-07 | — | — | US | disclosed |
| US-5385842-A | Anthraquinones as inhibitors of sulfide production from sulfate-reducing bacteria | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-01-31 | — | — | US | disclosed |
| EP-0525073-B1 | ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA | DU PONT (US) | 1994-05-25 | — | — | EP | disclosed |
| WO-1991015954-A1 | ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302797-A1 | COMBINATION THERAPIES FOR TREATING INFLAMMATION | TNF, MMP8, TSLP | NSD2 3273/4885HK1 1311/4885HKDC1 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.